Johnson & Johnson (NYSE: JNJ) released new data from the Phase 3 MajesTEC-3 study showing survival outcomes for a combination ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE